Perspectives - Page 32

Is Novartis’ RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug

In the last several years, RNA-targeted platforms yielded FDA/EMA approved therapies for ultra-rare metabolic and neurodegenerative diseases that address...

View Mar 24, 2020

Using Genomics to Track the Global Spread of COVID19

View Mar 23, 2020

Why Is Market Research Important?

Mar 13, 2020

Plans Are Worthless, but Planning Is Everything” – Biotech Leaders Discuss Key Challenges in Self-Commercialization for Late-Stage Assets

Mar 11, 2020

Old Dogs and New Tricks – Drug Repurposing for Rare Diseases

Feb 28, 2020

Kite (a Gilead Company) Release Unpublished Data Demonstrating the Key Determinants Influencing Durable Responses in Large B Cell Lymphoma Patients Treated With YESCARTA CAR-T Therapy

Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses achieved in relapsed/refractory (R/R) large B cell lymphoma patients treated with YESCARTA @ the CAR-TCR Summit Europe 2020.

Feb 26, 2020

Rare Diseases, Cell Therapies and the Value Conundrum – Food for Thought

Feb 26, 2020

Multi-Tumour-Associated Antigen-Specific (MultiTAA) T Cells Offer a Promising Therapeutic Approach vs. CAR-T To Effectively Combat an Array of Cancers

Feb 25, 2020

Accelerating Cell Therapies Into the Clinic – What’s Your Philosophy?

Feb 25, 2020

Patient Intelligence and Artificial Intelligence Combine To Bring Rare Disease Breakthroughs

Feb 25, 2020

CAR-T Therapy – Just As Much a Process as a Product!

Great talk by Dr. Dalip Sethi (Senior Scientist - Terumo BCT) @ the opening of the CAR-TCR Europe 2020 conference highlighting the many challenges associated with bringing CAR-T's from bench to bedside, both from a process and standardisation perspective.

Feb 25, 2020

Innovation in a Buyer’s Market: Standing Out in an Increasingly Crowded and Diversified Cancer Treatment Algorithm

View Feb 18, 2020

Oncology 2020, the Coming Decade’s Visionary Advances – Part III

View Feb 16, 2020

Hit the Road Running, an Introduction to Publications

View Feb 12, 2020

Seen Any Good Films Lately? Try the Rare Film Festival!

Feb 12, 2020

FDA Antimicrobial Drugs Advisory Committee Meeting (AMDAC) Recommends Approval of FETROJA (cefiderocol lyophilized powder)

On October 16, 2019, the Antimicrobial Drugs Advisory Committee (AMDAC) reviewed the New Drug Application (NDA) 209445 for cefiderocol lyophilized powder (Shionogi Inc.) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis due to gram-negative bacteria in patients with limited or no alternative treatment options.

View Feb 7, 2020